Organic Active Ingredients TRIZ Cases

Calcium sequestration agents reduce skin pigmentation by inhibiting melanin formation, avoiding irritation from conventional lightening compounds.

PPARgamma agonists treat hepatic and intestinal fibrosis by decreasing alpha-SMA expression, avoiding organ transplantation.

Substituted pyridine compounds block HIF-2α/ARNT heterodimerization to treat proliferative diseases without affecting HIF-1α activity.

Topical bacterial formulations deliver CRISPR-Cas systems to modulate the skin microbiome and restore barrier integrity.

Nanoparticle-encapsulated DNA clips regulate TH promoter activity to control dopamine production, overcoming blood-brain barrier penetration limits.

Retaining inulin within intact cell walls slows intestinal passage and boosts colonic butyrate production.

Upregulating ABCF1 expression via agonists modulates immune responses, reducing neuroinflammation and cytokine levels to treat major depressive disorder.

RENADYL probiotics convert urea to nitrogen gas through fermentation, restoring kidney function while reducing toxic waste accumulation in blood.

A transdermal patch delivers naltrexone using methyl oleate or isopropyl myristate as penetration enhancers.

Substituted quinolone derivatives inhibit AXL kinase activity through localized molecular interactions.

Maleate salt and specific crystal forms of a substituted 2-hydro-pyrazole derivative improve solubility and formulation prospects for CDK4/6-mediated diseases.

A pharmaceutical composition combining insulin, citrate, and treprostinil to enhance rapid pharmacokinetic uptake.

Novel fused bicyclic pyrrolo[3,2-d]pyrimidines inhibit Bruton's tyrosine kinase activity while improving metabolic stability over Ibrutinib.

Combining CDK4/6 inhibitors with fulvestrant treats hormone receptor-positive breast cancer.

2-phenylamino pyrrolopyrimidine compounds inhibit the ACK1 enzyme to disrupt tumor cell survival pathways.

IRGM stabilizes autophagy initiation via ULK1 and NOD2 complexes, resolving detection gaps in Crohn's disease therapy.

Diaminophenothiazine compounds disrupt assembled alpha-synuclein forms to address the root cause of Parkinson's disease neurodegeneration.

Amyloid-binding compounds inhibit protein aggregation and reduce plaque burden while crossing the blood-brain barrier to treat neurological disorders.

4-Azaindole derivatives act as positive allosteric modulators of the M1 muscarinic acetylcholine receptor.

Inactive bisphosphonates compete for hydroxyapatite binding sites to displace active drugs from bone, reducing osteonecrosis risk without systemic distribution.

Acidic hypertonic formulation treats osteoarthritis pain while preventing tissue irritation through synergistic ingredient buffering.

Stable pyrazinone crystal forms resolve specificity and stability trade-offs by selectively inhibiting FGFR2 and 3 kinases.

PPAR agonists reduce TNFα secretion and improve organ function, addressing dysregulated immune responses in sepsis.

Hydrophilic polymer swelling in a gastroretentive pyridostigmine matrix prevents initial burst release and dose dumping.

Dual-action piperazine compounds accelerate antidepressant effects by combining serotonin reuptake inhibition with 5-HT1A receptor agonism.

Transdermal cannabidiol gel bypasses gastrointestinal metabolism to reduce sleep apnea and seizures without somnolence.

Form AC1 crystalline solvate improves storage stability and flowability while eliminating hazardous reagents from the manufacturing process.

Phosphorylated compounds shift the hemoglobin oxygen binding curve to increase oxygen release from red blood cells, treating anemia and hypoxia.

Combining orexin receptor antagonists with serotonin agonists or NMDA antagonists promotes deep sleep and enhances cognitive function.

Benzimidazole-based JAK1 inhibitors target neuronal signaling pathways to alleviate chronic itch symptoms resistant to anti-inflammatory therapies.

A solid edaravone composition with an alkalizing agent dissolves rapidly in water to create an enterally administrable liquid.

Hydrophobic acid-drug complexes enable high loading and controlled release of AZD1152 hqpa.

Interpenetrating polymer substrate regulates compound release through adhesion control, resolving rapid uptake issues in hydrogel matrices.

Polyphenols extracted from cocoa cells regulate the skin cell cycle to maintain exponential growth, addressing hyperkeratinization without toxic effects.

Direct phenyl-nitrogen attachment expands structural diversity beyond spacer-linked inhibitors, enabling targeted treatment of asthma and atherosclerosis.

Measuring specific cereblon isoform levels guides personalized treatment selection, avoiding ineffective therapies caused by aberrant protein interference.

An omega-3 oil in water emulsion preserves isolated organs ex vivo.

Diamido arene analogs reduce myelotoxicity and treatment complications while maintaining potent antiviral efficacy against cytomegalovirus.

Timed dexamethasone and hydrocortisone doses suppress ACTH while minimizing metabolic side effects in late-onset congenital adrenal hyperplasia.

Macrocyclic and linear polyheterocyclic structures inhibit HCV NS3 protease, improving sustained response rates while reducing side effects.

Structural modifications of fermented macrolactones overcome drug resistance while minimizing additive side-effects.